For research use only. Not for therapeutic Use.
Voxalatamab（Cat No.:I042137）is an investigational bispecific monoclonal antibody designed to target two key proteins involved in tumor progression. It simultaneously binds to EGFR (epidermal growth factor receptor) and cMET (mesenchymal-epithelial transition factor), both of which are implicated in cancer cell growth and survival. By targeting these receptors, voxalatamab aims to inhibit tumor growth, overcome resistance mechanisms, and enhance immune system activity against cancer cells. It is being studied in clinical trials for its potential to treat various solid tumors, including non-small cell lung cancer (NSCLC), with a focus on improving patient outcomes.
| Catalog Number | I042137 |
| CAS Number | 2411871-58-2 |
| Purity | ≥95% |
